buy Lexapro




Arthritis
Genital Warts
Osteoporosis
Parasites




citalopram escitalopram Lexapro
Regulation of central serotonin transporters by chronic lithium: an autoradiographic study.

Carli M, Reader TA.

Centre de Recherche en Sciences Neurologiques, Departement de Physiologie, Faculte de Medecine, Universite de Montreal, Quebec, Canada.

The objectives of this study were to further characterize the effects of a chronic lithium (Li+) treatment on serotonin (5-HT) uptake sites, and to determine the eventual reversibility of the observed effects. Quantitative autoradiography experiments were carried out on sections from rat brain, using [3H]citalopram to label selectively the 5-HT transporters or uptake sites. In these experiments, we were able to saturate the 5-HT transporters using an isotopic dilution of the radioligand. The lowest densities of [3H]citalopram binding were measured in all cortical regions studied, with the highest cortical labelling in the anterior cingulate cortex. The rostral neostriatum presented a moderate density of labelling, with slightly higher levels in its ventral portion. Relatively high densities were measured in the globus pallidus, hippocampus, and hypothalamus. Finally, the highest densities were found in the brain stem. Indeed, the dorsal raphe nuclei as well as the substantia nigra were characterized by very high amounts of [3H]citalopram binding. The chronic administration of Li+ increased the density of 5-HT uptake sites in cortical regions, and significant differences were observed in the frontal, temporal, and entorhinal-piriform cortices, with an elevation, albeit not significant, in the anterior cingulate region. A significant increase was also observed in the lateral hypothalamus. Since the 5-HT uptake sites were studied with saturating concentrations of citalopram, we can propose that this increase in binding densities can be attributed to an increase in the number of 5-HT transporters. Interestingly, the only modifications observed were located in regions containing nerve terminals of 5-HT neurons, while regions with cell bodies remained unaffected. Moreover, these effects were completely reversed following a recovery of 48 h without Li . Also, there were no modifications in the density of 5-HT uptake sites after only 2 days of Li+. These results, suggesting an anatomically heterogenous increase in 5-HT uptake in chronically treated rats, are in accord with clinical observations and previous reports with homogenate binding assays. Finally, the conclusions from this study further support the importance of central 5-HT synaptic transmission in the pathophysiology and treatment of human affective disorders.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9268068&dopt=Abstract citalopram escitalopram Lexapro



citalopram escitalopram Lexapro
Early malnourished rats are not affected by anorexia induced by a selective serotonin reuptake inhibitor in adult life.

Barreto Medeiros JM, Cabral Filho JE, De Souza SL, Freitas Silva SR, Mendes Da Silva C, Deiro TC, Monteiro JM, Guedes RC, De Castro CM, Manhaes De Castro R.

Departamento Ciencias de la Nutricao, Universidade Federal da Bahia, Salvador, Brazil.

The effect of early postnatal malnutrition upon food intake and its modulation by the selective serotonin reuptake inhibitor (SSRI) citalopram, was investigated in adult rats. Sixty four Wistar rats were allocated to two groups, according to their mother's diet during lactation. Mothers receiving a 23% protein diet fed the well-nourished group; mothers receiving 8% protein diet fed the malnourished. After weaning, all rats received the 23% protein diet ad libitum. On the 120th day after birth, each nutritional group was divided in two subgroups (each one, n = 16) which received a single daily injection of citalopram (10 mg/kg) or saline (0.9% NaCl) for 14 days. Chronic treatment with citalopram decreased both the food intake and weight gain in the well-nourished rats, but not in the malnourished ones. These data are consistent with findings concerning the nutritional manipulation of the nervous system during its higher vulnerable phase, suggesting that early malnutrition alters the effect of treatment of SSRI in adult rats, and that malnutrition during the critical period of brain development affects the serotoninergic system.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12041877&dopt=Abstract citalopram escitalopram Lexapro



citalopram escitalopram Lexapro
Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity.

Wegener G, Volke V, Harvey BH, Rosenberg R.

Institute for Basic Psychiatric Research, Department of Biological Psychiatry, Skovagervej 2, DK-8240 Risskov, Denmark. wegener dadlnet.dk

Nitric oxide (NO) is an unconventional transmitter molecule in the nervous system, synthesized by nitric oxide synthase (NOS) following activation of the N-methyl-D-aspartate (NMDA) receptor. Several in vivo studies have demonstrated that NO modulates the extracellular levels of various neurotransmitters in the central nervous system, while serotonin (5-HT) re-uptake may be influenced by the NO pathway. Moreover, inhibitors of NOS exhibit antidepressant-like and anxiolytic-like properties in various animal models. Therefore, the aims of the present study were to clarify the involvement of distinct antidepressants acting on the serotonin re-uptake site in the regulation of the activity of hippocampal NOS in vitro, in vivo and ex vivo. We found that citalopram, paroxetine, imipramine and N(G)-nitro-L-arginine dose dependently decreased the hippocampal NOS activity in vitro. Moreover, local administration of citalopram, paroxetine, tianeptine, imipramine and N(G)-nitro-L-arginine significantly decreased the hippocampal NOS activity in vivo at a concentration significantly lower than in vitro. No effect on NOS activity following retrodialysis with 5-HT was observed. Acute (5 mg/kg, s.c.) and chronic (3 weeks, 20 mg/kg/24 h) systemic administration of citalopram did not influence NOS activity ex vivo. The effects on NOS represent a response to structurally dissimilar serotonergic antidepressants. However, since these data reflect effects on basal NOS activity, we believe that serotonergic antidepressants do not directly affect NOS at dosages used clinically, but the findings may reflect a secondary action of antidepressants on the glutamate NMDA receptor following their primary inhibitory action at the 5-HT transporter.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12480166&dopt=Abstract citalopram escitalopram Lexapro



citalopram escitalopram Lexapro
Repeated administration of antidepressant drugs affects the levels of mRNA coding for D1 and D2 dopamine receptors in the rat brain.

Dziedzicka-Wasylewska M, Rogoz R, Klimek V, Maj J.

Institute of Pharmacology, Polish Academy of Sciences, Krakow.

The present study examined the effects of acute and repeated administration of three antidepressant drugs (imipramine, citalopram and (+)-oxaprotiline) on the levels of mRNA coding for dopamine D1 and D2 receptors in the rat brain. Quantitive in situ hybridization with 35S-labelled oligonucleotide probes has been utilised. The level of mRNA coding for dopamine D1 receptor (D1 mRNA) is decreased following repeated administration of imipramine, both in the nucleus accumbens and in the striatum. On the other hand, the repeated administration of citalopram, the selective inhibitor of serotonin reuptake, resulted in an increase in the level of D1 mRNA in the striatum and in the core region of nucleus accumbens. A similar tendency, i.e.: an increase in the level of D1 mRNA was observed after repeated administration of (+)-oxaprotiline, a selective inhibitor of noradrenaline reuptake. The level of mRNA coding for dopamine D2 receptors (D2 mRNA) was increased in all the brain regions studied, both after administration of imipramine and citalopram. (+)-Oxaprotiline did not produce any statistically significant changes in the level of D2 mRNA. The results obtained in this study indicate that the levels of mRNA coding for dopamine D1 and D2 receptors are regulated by the antidepressant drugs. The changes concerning the dopamine D2 receptors are more consistent and fit in with the previously described binding and behavioral effects and seem to be important for the mechanism of action of antidepressant drugs.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9295182&dopt=Abstract citalopram escitalopram Lexapro



citalopram escitalopram Lexapro
Excretion of citalopram in breast milk.

Spigset O, Carieborg L, Ohman R, Norstrom A.

Division of Clinical Pharmacology, Norrland University Hospital, Umea, Sweden.

AIMS: The objective of this study was to measure to secretion of the selective serotonin uptake inhibitor citalopram in breast milk. METHODS: The excretion of citalopram in breast milk was studied at steady-state conditions in two patients with depression and in one healthy volunteer after ingestion of a single dose citalopram. RESULTS: Milk/serum concentration ratios based on single pairs of samples from the two patients ranged from 1.16 to 1.88. Based on milk concentration data from the patients, the absolute dose ingested by a suckling infant would be 4.3-17.6 micrograms kg-1 day-1, and the relative dose 0.7-5.9% of the weight-adjusted maternal dose. Based on area-under-the-time-concentration curves from the healthy volunteer, the milk/serum ratio was 1.00, the absolute dose to the infant during steady-state conditions would be 11.2 micrograms kg-1 day-1 and the relative dose 1.8% of the weight-adjusted maternal dose. CONCLUSION: The study shows that the relative dose to a suckling infant is close to that reported for fluoxetine, and higher than reported for fluvoxamine, paroxetine and sertraline.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9296327&dopt=Abstract citalopram escitalopram Lexapro



citalopram escitalopram Lexapro
Effects of the co-administration of 5-HT1A receptor antagonists with an SSRI in conditioned fear stress-induced freezing behavior.

Hashimoto S, Inoue T, Koyama T.

Department of Psychiatry, Hokkaido University School of Medicine, Sapporo, Japan.

The effects of the co-administration of the serotonin (5-HT) 1A receptor antagonists NAN-190 or (+)-WAY100135 with a selective 5-HT reuptake inhibitor (SSRI) citalopram on conditioned fear stress (CFS)-induced freezing behavior, which is the animal model of anxiety, were examined. The inhibitory effects of co-administration of NAN-190 (0.1-10 mg/kg) with citalopram on CFS-induced freezing were potent; in particular, at 0.1 and 0.25 mg/kg, NAN-190 significantly enhanced the effect of citalopram alone. At 0.1 mg/kg, (+)-WAY100135 also markedly enhanced the inhibitory effect of citalopram on freezing behavior. These findings suggest that 5-HT1A receptor antagonist, particularly at low doses, enhances the antifreezing effect of citalopram by blocking the autoreceptor-mediated negative feedback mechanisms of the 5-HT neuron. These experimental results concur with clinical findings that 5-HT1A receptor antagonist pindolol potentiates the effect of 5-HT reuptake inhibitors.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9300607&dopt=Abstract citalopram escitalopram Lexapro



citalopram escitalopram Lexapro
Tricyclic antidepressants prevent the differentiation of monocytes into macrophage-like cells in vitro.

Ying G, Karlsson H, DePierre JW, Nassberger L.

Department of Biochemistry, Unit for Biochemical Toxicology, Stockholm University, Stockholm, Sweden.

The investigation was designed to determine whether the two tricyclic antidepressant agents (TCAs) clomipramine and imipramine and the selective reuptake inhibitor citalopram affect differentiation of human monocytes to macrophage-like cells (MAC-LCs). We established primary adherent cultures of peripheral blood monocytes and monitored their morphology, capacity for phagocytosis and antigen expression during transformation to MAC-LCs. As expected, maturation of monocytes to MACs is accompanied by changes in morphology, elevated expression of the antigens CD16 and CD51 and an increase in the percentage of phagocytic cells. Treatment of cells with the TCAs clomipramine (40 micromol/L) or imipramine (100 micromol/L) and with citalopram (100 micromol/L), for 11 days resulted in the following observations: (1) monocytes treated with TCAs never developed the morphology characteristic of the MAC-LCs; (2) TCAs reduced the percentage of phagocytic cells; (3) TCAs had little influence on the expression of CD14, CD16, CD51, and HLA-DR. However, when added after monocyte differentiation into MAC-LCs, citalopram and clomipramine no longer reduced the percentage of phagocytic cells and these effects were not simply due to irreversible cytotoxicity. Thus clomipramine, imipramine, and citalopram inhibit differentiation of human monocytes into MAC-LCs in vitro, but in a reversible manner.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12484552&dopt=Abstract citalopram escitalopram Lexapro









Lexapro (escitalopram) References

Lexapro or escitalopram 1 | Lexapro or escitalopram 2 | Lexapro or escitalopram 3 | Lexapro or escitalopram 4 | Lexapro or escitalopram 5 | Lexapro or escitalopram 6 | Lexapro or escitalopram 7 | Lexapro or escitalopram 8 | Lexapro or escitalopram 9 | Lexapro or escitalopram 10 | Lexapro or escitalopram 11 | Lexapro or escitalopram 12 | Lexapro or escitalopram 13 | Lexapro or escitalopram 14 | Lexapro or escitalopram 15 | Lexapro or escitalopram 16 | Lexapro or escitalopram 17 | Lexapro or escitalopram 18 | Lexapro or escitalopram 19 | Lexapro or escitalopram 20 | Lexapro or escitalopram 21 | Lexapro or escitalopram 22 | Lexapro or escitalopram 23 | Lexapro or escitalopram 24 | Lexapro or escitalopram 25 | Lexapro or escitalopram 26 | Lexapro or escitalopram 27 | Lexapro or escitalopram 28 | Lexapro or escitalopram 29 | Lexapro or escitalopram 30 | Lexapro or escitalopram 31 | Lexapro or escitalopram 32 | Lexapro or escitalopram 33 | Lexapro or escitalopram 34 | Lexapro or escitalopram 35 | Lexapro or escitalopram 36 | Lexapro or escitalopram 37 | Lexapro or escitalopram 38 | Lexapro or escitalopram 39 | Lexapro or escitalopram 40 | Lexapro or escitalopram 41 | Lexapro or escitalopram 42 | Lexapro or escitalopram 43 | Lexapro or escitalopram 44 | Lexapro or escitalopram 45 | Lexapro or escitalopram 46 | Lexapro or escitalopram 47 | Lexapro or escitalopram 48 | Lexapro or escitalopram 49 | Lexapro or escitalopram 50 | Lexapro or escitalopram 51 | Lexapro or escitalopram 52 | Lexapro or escitalopram 53 | Lexapro or escitalopram 54 | Lexapro or escitalopram 55 | Lexapro or escitalopram 56 | Lexapro or escitalopram 57 | Lexapro or escitalopram 58



© DreamPharm.com